Disease relevance of pirbuterol hydrochloride

• We compared the initial and long-term effects of the beta-adrenergic agonist pirbuterol in 12 patients with chronic congestive heart failure [1].
• Pirbuterol effects substantial acute hemodynamic improvement in patients with chronic congestive heart failure without increasing requirements for coronary blood flow or myocardial oxygen delivery and without provoking myocardial ischemia [2].
• Therefore, we evaluated by cardiac catheterization and limb plethysmography the temporal cardiocirculatory responses of the new ingestible beta agonist pirbuterol in 10 coronary heart disease patients with severe congestive heart failure refractory to digitalis and diuretics [3].
• In conscious guinea pigs, pirbuterol antagonizes both histamine- and acetylcholine-induced bronchoconstriction and "microshock" anaphylaxis; combinations of pirbuterol and theophylline cause additive effects against histamine-induced bronchoconstriction [4].
• Nonbronchodilator effects of pirbuterol and ipratropium in chronic obstructive pulmonary disease [5].

High impact information on pirbuterol hydrochloride

• The density of beta-adrenergic receptors on lymphocytes from patients treated with pirbuterol was significantly depressed as compared with that of patients with heart failure of comparable severity but not treated with pirbuterol [1].
• Pirbuterol (PB), an oral beta-adrenergic-receptor agonist, has the pharmacologic effects of vasodilation and positive inotropy [6].
• Pirbuterol induced an increase in cardiac index (1.7 +/- 0.1 to 2.3 +/- 0.2 l/min/m2, p less than 0.05) and a fall in systemic vascular resistance (1884 +/- 118 to 1391 +/- 69 dyn-sec-cm-5, p less than 0.01) 2 hours after administration [2].
• We studied the effects of 20-30 mg of oral pirbuterol on myocardial metabolic and hemodynamic parameters in 12 patients (six with coronary artery disease) with chronic CHF refractory to standard medical therapy [2].
• Thus, oral pirbuterol provides beneficial hemodynamic effects in patients with severe left ventricular dysfunction and appears potentially useful for long-term management of low-output congestive heart failure [3].

Chemical compound and disease context of pirbuterol hydrochloride

• This study was designed to investigate and compare the haemodynamic and metabolic responses to pirbuterol and salbutamol in patients with congestive heart failure and coronary artery disease [7].
• The effects of single oral doses of pirbuterol 10 mg plus hydroxyzine 10 mg, and of pirbuterol 10 mg plus placebo, were compared in a single-blind cross-over trial in 17 adult patients with reversible airway obstruction [8].
• These results are discussed with respect to the utility of prenalterol and pirbuterol in congestive heart failure since possible tachyphylaxis to these drugs with chronic usage could limit their value [9].
• A comparative trial of pirbuterol and Tedral in patients with reversible airway obstruction [10].
• OBJECTIVE OF THE STUDY: To determine the maximal bronchodilator dose of procaterol and pirbuterol administered by inhalation with an without an aerochamber (Aerocâmera) to children with acute bronchial asthma attacks [11].

Biological context of pirbuterol hydrochloride

• We found no significant changes in the baseline resistance or in the bronchodilator response to pirbuterol during the course of the study, but there was a significant decrease in the functional residual capacity (FRC) [12].
• Generally, improvements of up to 25% are noted in forced expiratory volume in 1 second (FEV1) [versus baseline or placebo] in asthmatic patients treated with pirbuterol for several months [13].
• Pirbuterol is effective by the oral, intravenous and inhalation routes of administration [4].
• Pharmacokinetics and cardiopulmonary effects in dogs of sublingual pirbuterol, a new bronchodilator [14].
• A convenient method for study of the bioavailability of sublingual formulations is described, and the potential usefulness of a sublingual dosage form of pirbuterol is discussed [14].

Anatomical context of pirbuterol hydrochloride

• Decreased lymphocyte beta-adrenergic-receptor density in patients with heart failure and tolerance to the beta-adrenergic agonist pirbuterol [1].
• Studies of the receptor affinity of pirbuterol, timolol and nylidrin were carried out on iris-ciliary body membranes by competition binding with radioactive ligands [15].
• Differences between acute and long-term metabolic and endocrine effects of oral beta-adrenoceptor agonist therapy with pirbuterol for cardiac failure [16].

Associations of pirbuterol hydrochloride with other chemical compounds

• These include mainly the methylxanthines and possibly also the beta 2-adrenoceptor stimulating agents salbutamol, terbutaline, fenoterol and pirbuterol [17].
• INTERVENTIONS AND MEASUREMENTS: Patients were given either six puffs of the Maxair Autohaler (1,200 microg pirbuterol) plus saline solution by nebulizer (active Autohaler group) or six puffs placebo by Autohaler plus 2,500 microg albuterol via nebulizer (active nebulizer group) [18].
• CONCLUSION: Pirbuterol and ipratropium are equally effective bronchodilators in COPD [5].
• Treatment with pirbuterol for 3 months was associated with sustained increases in stroke volume and fasting plasma glucose and insulin, but there was loss of all other acute metabolic effects [16].
• The metabolic, hormonal and haemodynamic effects of oral pirbuterol, a new beta 2-adrenoceptor agonist, were studied acutely (n = 19) and after 3 months treatment (n = 11) in patients with severe heart failure receiving chronic frusemide therapy [16].

Gene context of pirbuterol hydrochloride

• We studied the effects of an oral beta2 selective bronchodilator, pirbuterol, in 12 male asthmatic patients over periods ranging from 6 to 23 months (mean, 13.8) [12].
• A new beta-2 adrenoceptor agonist (pirbuterol) in the treatment of ischaemic heart failure [19].
• Haemodynamic studies at rest and during exercise together with radionuclide ventriculography, pulmonary function and clinical well-being assessment were evaluated in ten patients with COPD and secondary pulmonary hypertension (mean PAP 25 mm Hg), before and after 6 months therapy with pirbuterol 20 mg thrice daily [20].
• In a controlled clinical crossover trial, the therapeutic effect of pirbuterol (CAS 38677-81-5) in the Autohaler was compared to that of salbutamol in a customary metered-dose aerosol in 17 children with asthma [21].

Analytical, diagnostic and therapeutic context of pirbuterol hydrochloride

• Blood analysis, urinalysis, and pulmonary function tests were performed and the pulmonary function tests were repeated approximately 2 hr after an oral dose of pirbuterol [12].
• Pirbuterol was given intravenously to nine normal men to determine the hemodynamic effects of intravenous injection of this rather selective beta 2-adrenoceptor agonist [22].
• METHODS: Pirbuterol and ipratropium bromide were administered by inhalation via a metered-dose inhaler to 12 and 14 patients with COPD, respectively, in a randomized, double-blind fashion [5].
• We have used a double-blind study with random allocation of patients to receive either pirbuterol or an identical-appearing placebo [23].
• When increases in CBF caused by pirbuterol before L-NAME were prevented by arterial constriction, CD increases were suppressed [24].

References